Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 6 2015

Print

Search Results for 'Financial Report: AstraZeneca'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published October 28, 2014
Merck 3Q Revenues: $10.6 billion  (-4%) 3Q Earnings: $842 million (-27%) YTD Revenues: $31.8 billion (-3%) YTD Earnings: $4.6 billion (+24%) Comments: Pharmaceutical sales were $9.1 billion in the quarter, down 4%. JANUVIA/JANUMET sales wer… Read More »
Published August 8, 2014
Integration of BMS assets offsets losses Read More »
Published April 29, 2014
Eliquis and AZ diabetes deal drive earnings in the quarter Read More »
By Kristin Brooks
Published January 3, 2014
Lead molecule and back-up compounds offer potential in cancer/inflammatory diseases Read More »
Published October 21, 2013
To explore compounds and targets with novel mechanisms with disease-modifying potential Read More »
Published February 2, 2012
Loss of nearly $2 billion in 2011 from generic competition, 7,300 more layoffs to come Read More »
AstraZeneca
Published July 1, 2010
#5 - AstraZeneca 15 Stanhope Gate London W1K 1LN (UK) Tel: (44) 00 7304 5000 Fax: (44) 020 7304 5151 www.astrazeneca.com Headcount 63,000   Year Established 1999  … Read More »
By Kevin Bottomley, Results Healthcare
Published June 3, 2014
Pharma companies are focusing on achieving cost efficiencies through specialization. Read More »
Published May 14, 2014
Will employ Ligand’s LTP Technology to improve lipid-lowering activity Read More »
CMOs and Final Dosage Manufacturing in China
By Oliver Mueller and Clifford Mintz, Suzhou Pharma Services and BioInsights
Published May 30, 2012
The far east market evolves Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On